{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 1-[2-[4-[1-(4-Methoxyphenyl)-2-nitro-2-phenylethenyl]phenoxy]ethyl]pyrrolidine
| image = Nitromifene.svg
| width = 250

<!--Clinical data-->
| tradename = 
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 10448-84-7
| CAS_supplemental = <br />5863-35-4 ([[citrate]])
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 22150
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 20796
| UNII = 5FS1NJ6Q8N
| KEGG = 
| ChEBI = 
| ChEMBL = 

<!--Chemical data-->
| C=27 | H=28 | N=2 | O=4
| SMILES = COC1=CC=C(C=C1)C(=C(C2=CC=CC=C2)[N+](=O)[O-])C3=CC=C(C=C3)OCCN4CCCC4
| StdInChI_Ref = 
| StdInChI = 1S/C27H28N2O4/c1-32-24-13-9-21(10-14-24)26(27(29(30)31)23-7-3-2-4-8-23)22-11-15-25(16-12-22)33-20-19-28-17-5-6-18-28/h2-4,7-16H,5-6,17-20H2,1H3
| StdInChIKey_Ref = 
| StdInChIKey = MFKMXUFMHOCZHP-UHFFFAOYSA-N
| synonyms = CI-728; CN-5518; CN-55945
}}

'''Nitromifene''' ([[International Nonproprietary Name|INN]]; also as the [[citrate]] [[salt (chemistry)|salt]] '''nitromifene citrate''' ([[United States Adopted Name|USAN]]), developmental code names '''CI-728''', '''CN-5518''', '''CN-55945''') is a [[nonsteroidal]] [[selective estrogen receptor modulator]] (SERM) related to [[triphenylethylene]]s like [[tamoxifen]] that was never marketed.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA880|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=880–}}</ref> It is a mixture of (''E'')- and (''Z'')-[[isomer]]s that possess similar [[antiestrogen]]ic activity.<ref name="KirkOthmer1980">{{cite book|author1=Raymond Eller Kirk|author2=Donald Frederick Othmer|title=Encyclopedia of chemical technology|url=https://books.google.com/books?id=yb9TAAAAMAAJ|year=1980|publisher=Wiley|isbn=978-0-471-02065-3|page=676}}</ref> The drug was described in 1966.<ref name="Elks2014" /> Along with tamoxifen, [[nafoxidine]], and [[clomifene]], it was one of the earliest SERMs.<ref name="pmid10368771">{{cite journal | vauthors = Jordan VC, Morrow M | title = Tamoxifen, raloxifene, and the prevention of breast cancer | journal = Endocr. Rev. | volume = 20 | issue = 3 | pages = 253–78 | year = 1999 | pmid = 10368771 | doi = 10.1210/edrv.20.3.0368 | url = }}</ref>

==References==
{{Reflist|2}}


{{Estrogen receptor modulators}}

[[Category:Abandoned drugs]]
[[Category:Nitro compounds]]
[[Category:Pyrrolidines]]
[[Category:Selective estrogen receptor modulators]]


{{genito-urinary-drug-stub}}